Trial Outcomes & Findings for The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention (NCT NCT01532934)

NCT ID: NCT01532934

Last Updated: 2016-12-12

Results Overview

Using timeline followback data, frequency of substance use was assessed for months three through six and presented as average percent days abstinent per month.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

105 participants

Primary outcome timeframe

three to six months post baseline

Results posted on

2016-12-12

Participant Flow

Recruitment took place at a jail diversion program in Upstate NY between 2009 and 2014.

Inclusion criteria were harmful substance use in the past 6 months and enrollment in a jail diversion program subsequent to being charged with a crime.

Participant milestones

Participant milestones
Measure
Brief Therapy
motivational enhancement therapy for substance use motivational enhancement therapy: Four 45-minute MET sessions
Standard Care
standard care standard care: standard care
Overall Study
STARTED
53
52
Overall Study
COMPLETED
39
39
Overall Study
NOT COMPLETED
14
13

Reasons for withdrawal

Reasons for withdrawal
Measure
Brief Therapy
motivational enhancement therapy for substance use motivational enhancement therapy: Four 45-minute MET sessions
Standard Care
standard care standard care: standard care
Overall Study
Lost to Follow-up
11
11
Overall Study
In controlled environment
3
2

Baseline Characteristics

The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Brief Motivational Intervention Plus Standard Care (BMI+SC)
n=53 Participants
Brief Motivational Intervention plus Standard Care; Individuals received up to 4 intervention sessions plus assessment and the usual range of services provided by Monroe County Pretrial
Standard Care (SC)
n=52 Participants
Standard Care: Individuals received assessment only, plus the usual range of services provided by Monroe County Pretrial
Total
n=105 Participants
Total of all reporting groups
Age, Continuous
33.1 years
STANDARD_DEVIATION 10 • n=5 Participants
33.8 years
STANDARD_DEVIATION 11.8 • n=7 Participants
33.4 years
STANDARD_DEVIATION 10.9 • n=5 Participants
Sex: Female, Male
Female
23 Participants
n=5 Participants
14 Participants
n=7 Participants
37 Participants
n=5 Participants
Sex: Female, Male
Male
30 Participants
n=5 Participants
38 Participants
n=7 Participants
68 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
21 Participants
n=5 Participants
24 Participants
n=7 Participants
45 Participants
n=5 Participants
Race (NIH/OMB)
White
24 Participants
n=5 Participants
26 Participants
n=7 Participants
50 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
8 Participants
n=5 Participants
2 Participants
n=7 Participants
10 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
53 participants
n=5 Participants
52 participants
n=7 Participants
105 participants
n=5 Participants
Psychopathy Checklist-Revised - Factor One (F1)
8.1 units on a scale
STANDARD_DEVIATION 4.3 • n=5 Participants
9.0 units on a scale
STANDARD_DEVIATION 4.4 • n=7 Participants
8.6 units on a scale
STANDARD_DEVIATION 4.3 • n=5 Participants

PRIMARY outcome

Timeframe: three to six months post baseline

Population: 105 adults (68 men and 37 women) were recruited in an urban pretrial jail diversion program. 78 (74.3%) were retained through six months. Of these, 73 were out of controlled environments (e.g., jail, inpatient treatment) for long enough to have their substance use data analyzed.

Using timeline followback data, frequency of substance use was assessed for months three through six and presented as average percent days abstinent per month.

Outcome measures

Outcome measures
Measure
BMI+SC
n=36 Participants
1. brief MI + standard care 2. standard care
Standard Care
n=37 Participants
Assessment only plus the usual range of pretrial services
Percent Days Abstinent Per Month From Drug Use
46.92 percentage of days abstinent
Standard Deviation 37.46
55.16 percentage of days abstinent
Standard Deviation 42.09

SECONDARY outcome

Timeframe: six months

A measure of consequences of drug and alcohol use across several domains (e.g., social, work, health), SIP-AD scores range from 0-45, with higher scores indicating higher levels of substance use consequences.

Outcome measures

Outcome measures
Measure
BMI+SC
n=36 Participants
1. brief MI + standard care 2. standard care
Standard Care
n=37 Participants
Assessment only plus the usual range of pretrial services
Shortened Inventory of Problems With Alcohol and Drugs (SIP-AD)
10.69 units on a scale
Standard Deviation 13.21
15.24 units on a scale
Standard Deviation 14.28

SECONDARY outcome

Timeframe: one year

New criminal charge vs. no new criminal charge at follow-up as indicated by county database.

Outcome measures

Outcome measures
Measure
BMI+SC
n=36 Participants
1. brief MI + standard care 2. standard care
Standard Care
n=37 Participants
Assessment only plus the usual range of pretrial services
New Criminal Charge
23 participants
22 participants

Adverse Events

Brief Motivational Intervention Plus Standard Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standard Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Marc T. Swogger, Ph.D.

University of Rochester

Phone: 585-275-7418

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place